Wellington Management Group LLP Has $73,000 Stock Position in Kyverna Therapeutics, Inc. $KYTX

Wellington Management Group LLP cut its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 86.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 37,828 shares of the company's stock after selling 236,586 shares during the period. Wellington Management Group LLP owned 0.09% of Kyverna Therapeutics worth $73,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Nuveen LLC bought a new position in shares of Kyverna Therapeutics during the first quarter worth approximately $92,000. Peapod Lane Capital LLC bought a new position in shares of Kyverna Therapeutics during the first quarter worth approximately $765,000. Bank of New York Mellon Corp increased its holdings in shares of Kyverna Therapeutics by 22.2% during the first quarter. Bank of New York Mellon Corp now owns 48,784 shares of the company's stock worth $94,000 after purchasing an additional 8,851 shares during the period. Rhumbline Advisers increased its holdings in shares of Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company's stock worth $61,000 after purchasing an additional 5,694 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Kyverna Therapeutics during the fourth quarter worth approximately $125,000. 18.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on KYTX shares. HC Wainwright raised their target price on shares of Kyverna Therapeutics from $5.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, August 29th. William Blair started coverage on shares of Kyverna Therapeutics in a report on Wednesday, August 20th. They set an "outperform" rating on the stock. One investment analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $16.60.

Kyverna Therapeutics Price Performance

NASDAQ:KYTX traded up $0.31 during mid-day trading on Friday, reaching $3.94. The stock had a trading volume of 217,394 shares, compared to its average volume of 283,574. The stock has a 50-day simple moving average of $3.58 and a two-hundred day simple moving average of $2.85. The stock has a market capitalization of $170.41 million, a PE ratio of -1.07 and a beta of 3.07. Kyverna Therapeutics, Inc. has a 12 month low of $1.78 and a 12 month high of $7.85.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.03. Equities analysts expect that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current year.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.